These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 28389462)

  • 1. Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.
    Taub JW; Berman JN; Hitzler JK; Sorrell AD; Lacayo NJ; Mast K; Head D; Raimondi S; Hirsch B; Ge Y; Gerbing RB; Wang YC; Alonzo TA; Campana D; Coustan-Smith E; Mathew P; Gamis AS
    Blood; 2017 Jun; 129(25):3304-3313. PubMed ID: 28389462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial.
    Hitzler J; Alonzo T; Gerbing R; Beckman A; Hirsch B; Raimondi S; Chisholm K; Viola S; Brodersen L; Loken M; Tong S; Druley T; O'Brien M; Hijiya N; Heerema-McKenney A; Wang YC; Schore R; Taub J; Gamis A; Kolb EA; Berman JN
    Blood; 2021 Dec; 138(23):2337-2346. PubMed ID: 34320162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group.
    Sorrell AD; Alonzo TA; Hilden JM; Gerbing RB; Loew TW; Hathaway L; Barnard D; Taub JW; Ravindranath Y; Smith FO; Arceci RJ; Woods WG; Gamis AS
    Cancer; 2012 Oct; 118(19):4806-14. PubMed ID: 22392565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.
    Lancet JE; Cortes JE; Hogge DE; Tallman MS; Kovacsovics TJ; Damon LE; Komrokji R; Solomon SR; Kolitz JE; Cooper M; Yeager AM; Louie AC; Feldman EJ
    Blood; 2014 May; 123(21):3239-46. PubMed ID: 24687088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.
    Rubnitz JE; Inaba H; Dahl G; Ribeiro RC; Bowman WP; Taub J; Pounds S; Razzouk BI; Lacayo NJ; Cao X; Meshinchi S; Degar B; Airewele G; Raimondi SC; Onciu M; Coustan-Smith E; Downing JR; Leung W; Pui CH; Campana D
    Lancet Oncol; 2010 Jun; 11(6):543-52. PubMed ID: 20451454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
    Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
    Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome.
    Kojima S; Sako M; Kato K; Hosoi G; Sato T; Ohara A; Koike K; Okimoto Y; Nishimura S; Akiyama Y; Yoshikawa T; Ishii E; Okamura J; Yazaki M; Hayashi Y; Eguchi M; Tsukimoto I; Ueda K
    Leukemia; 2000 May; 14(5):786-91. PubMed ID: 10803507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials.
    Wang H; Xiao X; Xiao Q; Lu Y; Wu Y
    Medicine (Baltimore); 2020 Jun; 99(24):e20094. PubMed ID: 32541448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.
    Freeman SD; Hills RK; Virgo P; Khan N; Couzens S; Dillon R; Gilkes A; Upton L; Nielsen OJ; Cavenagh JD; Jones G; Khwaja A; Cahalin P; Thomas I; Grimwade D; Burnett AK; Russell NH
    J Clin Oncol; 2018 May; 36(15):1486-1497. PubMed ID: 29601212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial.
    Uffmann M; Rasche M; Zimmermann M; von Neuhoff C; Creutzig U; Dworzak M; Scheffers L; Hasle H; Zwaan CM; Reinhardt D; Klusmann JH
    Blood; 2017 Jun; 129(25):3314-3321. PubMed ID: 28400376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891.
    Gamis AS; Woods WG; Alonzo TA; Buxton A; Lange B; Barnard DR; Gold S; Smith FO;
    J Clin Oncol; 2003 Sep; 21(18):3415-22. PubMed ID: 12885836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.
    Creutzig U; Ritter J; Zimmermann M; Reinhardt D; Hermann J; Berthold F; Henze G; Jürgens H; Kabisch H; Havers W; Reiter A; Kluba U; Niggli F; Gadner H
    J Clin Oncol; 2001 May; 19(10):2705-13. PubMed ID: 11352963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
    Röllig C; Serve H; Hüttmann A; Noppeney R; Müller-Tidow C; Krug U; Baldus CD; Brandts CH; Kunzmann V; Einsele H; Krämer A; Schäfer-Eckart K; Neubauer A; Burchert A; Giagounidis A; Krause SW; Mackensen A; Aulitzky W; Herbst R; Hänel M; Kiani A; Frickhofen N; Kullmer J; Kaiser U; Link H; Geer T; Reichle A; Junghanß C; Repp R; Heits F; Dürk H; Hase J; Klut IM; Illmer T; Bornhäuser M; Schaich M; Parmentier S; Görner M; Thiede C; von Bonin M; Schetelig J; Kramer M; Berdel WE; Ehninger G;
    Lancet Oncol; 2015 Dec; 16(16):1691-9. PubMed ID: 26549589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia.
    Lee JH; Joo YD; Kim H; Bae SH; Kim MK; Zang DY; Lee JL; Lee GW; Lee JH; Park JH; Kim DY; Lee WS; Ryoo HM; Hyun MS; Kim HJ; Min YJ; Jang YE; Lee KH;
    Blood; 2011 Oct; 118(14):3832-41. PubMed ID: 21828126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitoxantrone Versus Liposomal Daunorubicin in Induction of Pediatric AML With Risk Stratification Based on Flow Cytometry Measurement of Residual Disease.
    Tierens A; Arad-Cohen N; Cheuk D; De Moerloose B; Fernandez Navarro JM; Hasle H; Jahnukainen K; Juul-Dam KL; Kaspers G; Kovalova Z; Lausen B; Norén-Nyström U; Palle J; Pasauliene R; Jan Pronk C; Saks K; Zeller B; Abrahamsson J
    J Clin Oncol; 2024 Jun; 42(18):2174-2185. PubMed ID: 38603646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of minimal residual disease in patients with t(8;21) acute myeloid leukemia in Japan.
    Narimatsu H; Iino M; Ichihashi T; Yokozawa T; Hayakawa M; Kiyoi H; Takeo T; Sawamoto A; Iida H; Tsuzuki M; Yanada M; Naoe T; Suzuki R; Sugiura I
    Int J Hematol; 2008 Sep; 88(2):154-158. PubMed ID: 18553224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial.
    Schaich M; Parmentier S; Kramer M; Illmer T; Stölzel F; Röllig C; Thiede C; Hänel M; Schäfer-Eckart K; Aulitzky W; Einsele H; Ho AD; Serve H; Berdel WE; Mayer J; Schmitz N; Krause SW; Neubauer A; Baldus CD; Schetelig J; Bornhäuser M; Ehninger G
    J Clin Oncol; 2013 Jun; 31(17):2094-102. PubMed ID: 23630210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children's Oncology Group.
    Elgarten CW; Wood AC; Li Y; Alonzo TA; Brodersen LE; Gerbing RB; Getz KD; Huang YV; Loken M; Meshinchi S; Pollard JA; Sung L; Woods WG; Kolb EA; Gamis AS; Aplenc R
    Pediatr Blood Cancer; 2021 Dec; 68(12):e29281. PubMed ID: 34596937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.
    Ravandi F; Assi R; Daver N; Benton CB; Kadia T; Thompson PA; Borthakur G; Alvarado Y; Jabbour EJ; Konopleva M; Takahashi K; Kornblau S; DiNardo CD; Estrov Z; Flores W; Basu S; Allison J; Sharma P; Pierce S; Pike A; Cortes JE; Garcia-Manero G; Kantarjian HM
    Lancet Haematol; 2019 Sep; 6(9):e480-e488. PubMed ID: 31400961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome.
    Taga T; Tanaka S; Hasegawa D; Terui K; Toki T; Iwamoto S; Hiramatsu H; Miyamura T; Hashii Y; Moritake H; Nakayama H; Takahashi H; Shimada A; Taki T; Ito E; Hama A; Ito M; Koh K; Hasegawa D; Saito AM; Adachi S; Tomizawa D
    Leukemia; 2021 Sep; 35(9):2508-2516. PubMed ID: 33589754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.